AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
172.48
+2.84 (1.67%)
At close: Jul 28, 2026, 4:00 PM EDT
172.48
0.00 (0.00%)
After-hours: Jul 28, 2026, 6:30 PM EDT
AstraZeneca Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 61,366 | 58,739 | 54,073 | 45,811 | 44,351 | 37,417 |
Revenue Growth | 8.61% | 8.63% | 18.04% | 3.29% | 18.53% | 40.58% |
Gross Profit Gross Profit Growth | 50,246 | 48,106 | 43,866 | 37,543 | 31,960 | 24,980 |
Operating Income Operating Income Growth | 13,971 | 13,743 | 10,003 | 8,193 | 3,757 | 1,056 |
Net Income Net Income Growth | 10,446 | 10,225 | 7,035 | 5,955 | 3,288 | 112 |
Earnings Per Share EPS Growth | 6.69 | 6.54 | 4.50 | 3.81 | 2.11 | 0.08 |
EPS Growth | 25.99% | 45.33% | 18.11% | 80.57% | 2537.50% | -96.72% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Oncology Oncology Growth | 27,786 | 25,618 | 20,275 | 17,145 | 14,631 | 12,940 |
BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) Growth | 12,275 | 12,774 | 12,448 | 10,585 | 9,188 | 8,088 |
BioPharmaceuticals: Respiratory & Immunology PR (R&I) BioPharmaceuticals: Respiratory & Immunology PR (R&I) Growth | 9,381 | 8,866 | 7,416 | 6,107 | 5,765 | 6,034 |
BioPharmaceuticals Infectious Disease PR (ID) BioPharmaceuticals Infectious Disease PR (ID) Growth | 1,171 | 1,268 | 1,058 | 1,012 | 4,736 | 4,665 |
Rare Disease Rare Disease Growth | 9,700 | 9,126 | 8,668 | 7,764 | 7,053 | 3,110 |
Other Medicines Other Medicines Growth | 959 | 988 | 1,073 | 1,176 | 1,625 | 1,704 |
Collaboration Collaboration Growth | - | 99 | 3,135 | 2,022 | 1,353 | 876 |
Revenue (Total) Revenue (Total) Growth | 61,366 | 58,739 | 54,073 | 45,811 | 44,351 | 37,417 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 4,968 | 5,741 | 5,654 | 5,962 | 6,405 | 6,398 |
Total Debt Total Debt Growth | 32,239 | 29,622 | 30,295 | 28,622 | 29,232 | 30,781 |
Net Cash (Debt) Net Cash Growth | -27,271 | -23,881 | -24,641 | -22,660 | -22,827 | -24,383 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -17.47 | -15.29 | -15.77 | -14.51 | -14.63 | -17.09 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 13,700 | 14,575 | 11,861 | 10,345 | 9,808 | 5,963 |
Capital Expenditures CapEx Growth | -3,032 | -2,810 | -1,924 | -1,361 | -1,091 | -1,091 |
Free Cash Flow Free Cash Flow Growth | 10,668 | 11,765 | 9,937 | 8,984 | 8,717 | 4,872 |
Free Cash Flow Growth | -4.54% | 18.40% | 10.61% | 3.06% | 78.92% | 26.94% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 81.88% | 81.90% | 81.12% | 81.95% | 72.06% | 66.76% |
Operating Margin | 22.77% | 23.40% | 18.50% | 17.88% | 8.47% | 2.82% |
Pretax Margin | 20.51% | 21.11% | 16.07% | 15.06% | 5.64% | -0.71% |
Profit Margin | 17.03% | 17.42% | 13.02% | 13.01% | 7.42% | 0.31% |
FCF Margin | 17.38% | 20.03% | 18.38% | 19.61% | 19.65% | 13.02% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 3.230 | 3.200 | 3.100 | 2.900 | 2.900 | 2.870 |
Dividend Per Share Growth | 3.19% | 3.23% | 6.90% | 0% | 1.04% | 2.50% |
Dividend Yield | 1.87% | 1.83% | 2.30% | 2.15% | 2.07% | 2.35% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 25.56 | 26.83 | 28.89 | 35.29 | 64.56 | 1448.13 |
P/FCF Ratio | 25.03 | 23.14 | 20.28 | 23.20 | 24.22 | 36.84 |
PS Ratio | 4.35 | 4.63 | 3.73 | 4.55 | 4.76 | 4.80 |